TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02317224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Hole subxiphorid and subcostal approach
Description: 3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans sternal approach
Description: Trans sternal approach anterior mediastinum tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS approach
Description: Video-assisted thoracoscope anterior mediastinum tumor resection
Study: NCT01413672

Intervention type: DEVICE
Intervention: Use of CASTLE barrier
Description: Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
Study: NCT00981474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood pressure maintenance based on cerebral blood flow autoregulation measurement
Description: Blood pressure lowered or raised

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Institutional standard of care.
Study: NCT01849120

Intervention type: DEVICE
Intervention: EQUANOX Advance 8004CB sensor
Description: The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
Study: NCT00819403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe/simvastatin
Description: Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
Study: NCT03313219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab Injection
Description: Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
Study: NCT00764192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample before and after a single HD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) before and after a single HD
Description: measuring of the flow-mediated dilation using high-resolution ultrasound
Study: NCT02606955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIA DW
Description: All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
Study: NCT01190215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: One Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)
Description: Two Intramuscular injections
Study: NCT04199533

Intervention type: BEHAVIORAL
Intervention: RUBI
Description: Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis

Intervention type: BEHAVIORAL
Intervention: RUBIES
Description: School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis

Intervention type: BEHAVIORAL
Intervention: RUBIES
Description: School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
Study: NCT02185885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increased bloodpressure during CPB.
Study: NCT02446925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surefire® Infusion System
Description: Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard End-hole catheter
Description: Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
Study: NCT02482272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 100mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Adefovir 10mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir 10mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 1mg/day orally
Study: NCT05800808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Intervals
Description: 8x4 min cycling bouts at 85% of VO2peak

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Exercise
Description: 81 minutes of cycling at 50% VO2peak
Study: NCT01671839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue release with the Cabochon System
Description: Device: Subcutaneous tissue release
Study: NCT01279330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-signed Letter
Description: Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: No intervention (Patients receive by mail the materials needed for stool samples).
Study: NCT02670252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (TBI)
Description: Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
Study: NCT05039762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
Study: NCT03368885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of existing platforms VHSND
Description: Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategic use of data
Description: Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
Study: NCT03033316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT05039762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
Study: NCT02163655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE
Description: Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
Study: NCT01619657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% Hypertonic Saline (HS), 4mL
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Isotonic Saline (IS), 4mL
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Study: NCT01449240

Intervention type: OTHER
Intervention: No treatment
Study: NCT02914184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV PCV-free liquid vaccine
Description: Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV PCV-free liquid vaccine
Description: Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV PCV-free liquid vaccine
Description: Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
Study: NCT00612222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC MART-1 Vaccine
Description: ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
Study: NCT03690934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistula-tract laser closure (FiLAC™)
Description: The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
Study: NCT02989779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK1 Antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NK1 Antagonist
Study: NCT03690934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar coagulation of fistulous tract
Description: The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
Study: NCT03644069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SQ injections: 32 in total, at twice weekly intervals
Study: NCT02436083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic (use of penicilline, unacid, cefuroxime)
Description: prophylactic antibiotics
Study: NCT00426322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bovine bone mineral particles (Bio-Oss®)
Description: bovine bone mineral particles used for sinus augmentation prior to dental implant placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bovine bone mineral particles (Bio-Oss®)
Description: bovine bone mineral particles used for sinus augmentation prior to dental implant placement
Study: NCT01678443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: indium In 111 anti-CD45 monoclonal antibody BC8
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD45 monoclonal antibody BC8
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study: NCT00894634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate
Study: NCT03413254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine follow-up
Description: Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up
Description: Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second look DLS
Description: Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second look DLS
Description: Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third look DLS
Description: Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
Study: NCT00708526

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care for phase one anesthesia care
Description: Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick Emergence Device
Description: The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
Study: NCT01478113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine/dextroamphetamine
Description: The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Well-being therapy
Description: Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Well-being therapy
Description: Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
Study: NCT02989779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Study: NCT04052386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICCS
Description: Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. The personalized feedback intervention included tailored feedback on drinking quantity and frequency of alcohol, BAC, alcohol-related consequences, normative perceptions of peer drinking, alcohol outcome expectancies, family history of risk, and financial costs of alcohol. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
Study: NCT03781089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Oral Powder Product
Description: Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
Study: NCT00714532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expert System Only
Description: Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Expert System
Description: The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction
Study: NCT03355755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EksoGT with SmartAssist software
Description: Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
Study: NCT02734108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
Study: NCT01400230

Intervention type: PROCEDURE
Intervention: diagnostic procedures CCTA, CAG, IVUS and FFR
Description: Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
Study: NCT02629055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory EMG
Description: Titration of non-invasive ventilation on surface respiratory muscle activity